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Abstract
Objectives: several studies have shown persistent neu-
rocognitive impairment in patients with a bipolar af-
fective disorder (BD) even in euthymia as well as in
patients  with  a  schizoaffective  disorder  (saD).  the
aim of our study was to compare the neuropsycholog-
ical  performance  between  these  two  groups.  Con-
founding variables were controlled to enhance our un-
derstanding of cognitive dysfunction in both BD and
saD. 
Methods: several domains of neurocognitive function,
executive function, memory, attention, concentration
and perceptuomotor function were examined in 28 eu-
thymic saD patients and 32 BD patients by using a
neuropsychological  test  battery.  the  Hamilton  De-
pression Rating scale (HaMD), Montgomery-asberg
Depression Rating scale (MaDRs) and young Mania
Rating  scale  (yMRs)  were  used  to  evaluate  the  pa-
tients’ clinical status. Data analysis was performed by
using  a  multivariate  analysis  of  covariance  (anCo-
va/ManCova). 
Results: Euthymic saD patients showed greater cogni-
tive impairment than euthymic BD patients in the test-
ed domains including declarative memory and atten-
tion. Putative significant group differences concerning
cognitive flexibility vanished when controlled for de-
mographic and clinical variables. age and medication
were  robust  predictors  to  cognitive  performance  of
both saD and BD patients. 
Conclusions: our results point out the worse cognitive
outcome of saD compared to BD patients in remis-
sion. Remarkably, the variance is higher for some of
the test results between the groups than within each
group, this being discussed in light of the contradic-
tive concept of saD.
Key  words:  bipolar disorder, schizoaffective disorder,
cognition, neuropsychology 
IntRoDuCtIon
It has been estimated that between 0.5% and 0.8% of
the  general  population  suffer  from  a  schizoaffective
disorder (saD) [3]. Despite slightly different concepts
of  the  DsM-Iv  and  ICD-10  diagnostic  criteria,  the
core feature of saD in both manuals is the concur-
rent or consecutive occurrence of psychotic and affec-
tive  symptomatology.  the  ongoing  debate  whether
saD does really exist or is rather an artificial or inter-
mediate category, particularly arises from the differing
saD diagnostic criteria. In a five-years retrospective
study of 61 patients with initial diagnosis of saD a
proportion of 37 patients shifted to the diagnosis of
bipolar disorder (BD) during the observational period
[36]. Consequently, Marneros and goodwin [30] sug-
gested an adaptation of the ICD-10 classification and
to subsume saD to the affective category rather than
to the spectrum of schizophrenia (sz).
It is further known that cognitive impairment is a
characteristic feature of saD and considered to be a
core symptom of both BD and sz. Cognitive deficits
are neither exclusively a result of the affective sympto-
matology nor solely a consequence of pharmacologi-
cal treatment [20].  
Most of the studies concerning cognitive function-
ing  have  shown  cognitive  deficits  in  bipolar  depres-
sion. In recent years, persistent cognitive deficits have
been reported even in euthymia in about one third of
bipolar patients [19]. Patients with BD exhibit a re-
duced  verbal  [51]  and  spatial  working  memory  [16].
Even when controlled for age, premorbid IQ or resid-
ual  depressive  symptomalogy,  the  performance  is
poorer concerning learning, short and delayed recall as
well as recognition tasks [32]. the verbal recovery of
information best predicts the outcome of psychoso-
cial functioning of bipolar patients, and consequently
correlates with serious occupational or relational prob-
lems [31]. However, Clark, Iversen and goodwin [9]
also controlled for mild affective symptoms and found
a reduced sustained attention, only. a reduced selec-
tive  attention  was  evaluated  using  the  stroop  word
Colour test [50]. Moreover, severe deficits in execu-
tive  dysfunction  were  observed  in  many  studies.  a
prolonged planning time [40], reduced verbal fluency
[22] and impaired working memory [46] were the main
cognitive domains found in these studies. the result
was that the cognitive flexibility was also impaired, and
appeared  to  be  distinctive  for  bipolar  patients  with
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5. Assion_Umbruchvorlage  12.02.10  11:12  Seite 70psychotic features [1]. Despite these convincing data,
cognitive performance is significantly poorer in many,
but not all executive tasks, thompson et al. [47] char-
acterized  the  patient’s  executive  deficit  as  a  generic
deficit in controlled processing. a meta-analytic review
[38] about cognitive deficits in euthymic BD patients
analysed the largest effect size (d ≥0.8) for aspects of
executive  function  and  verbal  learning.  on  the  one
hand, bipolar patients were partly aware of these cog-
nitive deficits, on the other, they also showed poorer
neuropsychological  performance  without  subjective
complaints [33]. nevertheless, there are BD patients
with no neuropsychological deficits. according to re-
cent  data  approximately  half  of  the  patients  per-
formed without significant difference to healthy con-
trols [3]. Patients with sz also suffer from widespread
neuropsychological  deficits,  including  speed  of  pro-
cessing, attention, working memory, verbal and visual
learning as well as reasoning, problem solving and so-
cial cognition [20]. the impairment is considered to be
more severe in sz than in BD [25] and is not attenuat-
ed when statistically controlled for IQ, which was sig-
nificantly lower in patients with sz [43]. Burdick et al.
[7] found the neurocognitive performance to be longi-
tudinally  more  stable  in  sz  than  in  BD.  the  latter
showed better symptom remission in a 5-years follow-
up, especially in short-term and long-term memory. 
Despite the great plenty of studies comparing BD
with sz [11, 18, 34], only a few studies distinctly com-
pared cognitive deficits of BD patients with saD pa-
tients. torrent et al. [48] found significant impairment
in verbal learning and memory in saD patients. glahn
et al. [17] reported that saD patients neither signifi-
cantly differ from BD patients nor from sz patients in
measures of verbal working memory (spatial delayed
response  task,  forward  and  backward  digit  span).
szoke et al. [45] concluded that on the one hand saD
patients closely resemble sz patients in some of the
cognitive domains, on the other hand cognitive deficits
are ranging on a continuum from sz to BD.
It is relevant to mention the negative effect of psy-
chotropic medication on cognition. It is well known,
that psychotropic drugs with an antidopaminergic pro-
file (e.g. D2/D3 antagonists) induce on one hand a
mesocortical hypodopaminergic state, that is correlat-
ed with negative symptoms and cognitive impairment,
and on the other hand mesolimbic hyporeactivity that
is associated with depressive symptoms. 
the  aim  of  our  study  was  to  contribute  data  of
cognitive functioning of saD and BD patients in eu-
thymia further and to evaluate the effect sizes of con-
founding variables on neuropsycho-logical impairment
for both disorders. 
PatIEnts anD MEtHoDs
suBJECts
the study was conducted at the Department of Psy-
chiatry  and  Psychotherapy,  Ruhr  university  of
Bochum, germany. thirty-two Bipolar I and twenty-
eight patients with schizoaffective disorder of either
gender aged between 18 and 75 years were recruited.
the wide age range was intended to allow an analysis
of a subsample with elder age.
all were euthymic and met the DsM-Iv criteria of
bipolar  or  schizoaffective  disorder.  Diagnoses  were
confirmed using the structured Clinical Interview for
DsM-Iv (sCID). subjects with disorders that could be
related to neuropsychological impairment (e.g. any sig-
nificant neurological or medical condition, for instance
cardiovascular or pulmonary disease, history of head
injury, neurodegenerative disorder, mental retardation,
substance  dependence  within  the  past  year,  electro-
convulsive  therapy  in  the  past  6  months,  treatment
with benzodiazepines) were excluded from the study.
no structural brain abnormalities were reported from
the  history  of  the  patients  or  from  neuroimaging
scans.
after clinical remission for at least 3 months, pa-
tients were screened for euthymia on the day of neu-
ropsychological  testing  using  Hamilton  Depression
Rating  scale  (HaMD)  or  Montgomery-asberg  De-
pression rating scale (MaDRs) and young Mania Rat-
ing scale (yMRs). all of the raters attended a rater-
training and the interrater agreement was substantial
(k = 0.71). HaMD scores had to be less than 8 points
each, MaDRs scores were lower than 12 points. Pa-
tients of the saD sample did not completly fulfill the
remission criteria. 
with  respect  to  medication  patients  in  the  saD
group were less often on a monotherapy with antipsy-
chotics, but did not differ to the BD group concerning
combination therapy or the proportion of compounds
with D2/D3 receptor antagonistic properties.
all patients gave written informed consent to par-
ticipate in the study after the procedures had been ful-
ly explained. Ethic approval for the study was granted
by  the  ethics  committee  of  the  Ruhr  university  of
Bochum. the study was supported by a grant from the
Ruhr university of Bochum, germany (foRuM).
nEuRoPsyCHologICal assEssMEnt
the neuropsychological test battery was composed of
multiple well-established and some innovative instru-
ments: Mwt-B, d2-test, tMt, subsection of waIs-R,
vlMt and logical memory test.
Estimated  premorbid  intelligence,  MWT-B  [26]: In a
37-item  task,  the  patients  had  to  identify  one  right
word out of four artificial words. this measure deliv-
ers an estimate of current intellectual function and a
clue to premorbid intelligence. 
Attention,  psychomotor  speed  and  cognitive  flexibility,
d2- test [6]: a presentation of 47 letters (d or p) with
two  bars  above  or  under  a  letter  in  14  consecutive
rows.  Patients  have  to  pass  through  a  row  within  a
time frame of 20 seconds. Parameters are speed (all
marked letters, gz),  accurateness (f%) and concen-
tration  performance  (number  of  correct  marks  and
less confusion mistakes, Kl).
Trail making test, TMT [27, 35, 37]: Part a is a mea-
sure for psychomotor speed, part B is used to measure
executive functioning and reflects the ability to shift
strategy and visuospatial working memory.
Declarative memory and verbal learning, digit span and
block span subtest, subsection of  Wechsler Adult Intel-
ligence Scale [49, 21]: subjects have to repeat a fixed
random series of verbal (digit) and visual (block) num-
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verse (backward) order. auditory attention, visual at-
tention and short-term retention capacity are assessed
in addition to the ability to manipulate the information
in the verbal and visual working memory. 
Verbal  Learning  Memory  Test,  VLMT  [23]:  the
vlMt is an equivalent to the auditory verbal learn-
ing test (avlt) and comprises a list-learning task of
15 semantic independent words. It contains five imme-
diate  free  recall  trials  of  a  list  a,  which  provides  a
global measure of learning performance. an interfer-
ence list B is presented afterwards and a short-delay
recall of list a in free form is required. after a time
span  of  20  minutes,  list  a  is  repeatedly  questioned
(long delay free recall).
Logical memory, emotional versus neutral text samples
[8]: for resolving the question whether patients bene-
fit from an emotional content of an information in
terms of a higher reproduction performance in com-
parison to a neutral text. Recognition ability of both
sixteen item versions is recorded.
statIstICal analysEs
Baseline demographic measures and clinical character-
istics (table 1) were compared between bipolar and
schizoaffective  patients  using  one-way  analyses  of
variance (anova) and Chi-square tests. Performance
on neuropsychological tests was compared by means
of multivariate analyses of covariance (ManCova).
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Table 1. Demographic and clinical characteristics of 32 bipolar and 28 schizoaffective disorder patients. 
Demographic and Bipolar disorder  schizoaffective ANOVA
clinical variables patients (n = 32 ) patients (n = 28)
Mean SD Mean SD F df P
Age 48.0  14.92 45.61 10.5 0.5 1; 58 0.48 
YMRS score 2.34 2.67 7.63 6.37 18.29 1; 57 <0.01
HAMD score 4.5 2.81
MADRS score 10.87 8.01
Years since having a 11.56 9.61 21.39 11.34 12.04 1; 53 <0.01
pychiatric diagnosis
MWT-B score 114.69 15.54 104.64 16.13  5.98 1; 58 0.02 
n% n% c2 df P
Sex
Male 13 40.6 7 25 1.64 1 0.2
Female 19 59.4 21 75
Education:
No school 0027.7 2.55 1 0.11
Only school 6 18.8 5 19.2 0.002 1 0.96
School and futher 17 53.1 14 53.8 0.003 1 0.96
education
Highschool 9 28.1 5 19.2 0.62 1 0.43
Current mediacation:
AD only 2 6.3 001.75 1 0.19
MS only 3 9.4 7 25.9 2.85 1 0.09
NL only 6 18.8 005.83 1 0.02
AD & MS 11 34.4 3 11.1 4.38 1 0.04
AD & NL 7 21.9 4 14.8 0.48 1 0.49
MS & NL 16 50 16 59.3 0.51 1 0.48
All 7 21.9 2 7.4 2.37 1 0.12
Neither 1 3.1 2 7.4 0.56 1 0.46
Last episode:
Maniac 18 56.3 16 57.1 0.01 1 0.94
Depressiv 11 34.3 4 14.3 3.21 1 0.07
Mixed 3 9.4 5 17.9 0.93 1 0.34
anova = analysis of variance; yMRs = young Mania Rating scale; HaMD = Hamilton Depression Rating scale; Mwt-B =
Estimated premorbid intelligence; aD = antidepressants; Ms = mood stabilizer; nl = antipsychotics
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found to be significantly different between these two
groups,  were  included  in  the  analyses  as  covariates.
Consecutively,  one-way  analyses  of  covarinace  (an-
Cova)  were  used  to  detect  group  differences  with
single  test  dimenions.  Estimates  of  effect  size  were
calculated  for  untransformed  data  with  the  formula
mbipolar - mschizoaffective —————————— = d [24].
spooled
additionally, a stepwise regression analysis was con-
ducted in order to assess the association of clinical and
demographic variables with cognitive functioning. age,
gender, years since having a psychiatric diagnosis, hos-
pitalisation rate, number of outpatient treatments, pre-
morbid IQ, yMRs scores, HaMD score resp. MaDRs
score and current medication were used as variables. 
In order to prevent an apha-inflation due to multi-
ple  testing,  only  results  with  a  significance  level  at
P<0.01  were  interpreted.  Having  stated  no  a-priori
hypothesis regarding the direction of differences only
two-tailed  significance  tests  were  computed.  Data
analysis was performed using statistical Packages for
social sciences (sPss) version 14.0 [44].
REsults
DEMogRaPHIC MEasuREs anD ClInICal
CHaRaCtERIstICs
sociodemographic  and  clinical  variables  are  summa-
rized separately for 32 Bipolar I and 28 schizoaffective
patients (table 1). groups were well matched in terms
of age, gender ratio, education and the type of the last
episode. the duration of illness differed significantly
between the saD (21,39 years) and BD (11,56 years)
group.  gender  differences  were  obvious  in  both
groups with the highest rate of females in the saD
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Table 2. neuropsychological testing results (estimated means).
Test dimension Bipolar patients  Schizoaffective  MANCOVA/ ANCOVA#
(n = 32) patients (n = 28)
Mean SD Mean SD F df Pd
Attention and 
psychomotor speed
6.94 4; 44 <0.01
d2 speed (GZ) 454.60 106.56 494.81 102.24 1.12 1; 47 0.30 0.39
d2 accurateness (F%) 14.36 8.32 30.50 17.52 12.37 1; 47 <0.01 1.18
d2 concentration (KL) 149.57 58.66 140.95 63.08 0.16 1; 47 0.70 0.14
TMT-A (sec.) 42.61 22.71 64.21 42.88 2.91 1; 47 0.09** 0.63
Declarative memory 7.27 7; 41 <0.01
digit span forward 9.35 1.8 8.12 2.35 2.83 1; 47 0.10 0.59
digit span backward 6.21 2.36 5.65 2.04 0.50 1; 47 0.48 0.25
block span forward 8.50 2.04 9.99 2.02 3.96 1; 47 0.05 0.73
block span backward 7.16 2.19 5.68 2.41 4.06 1; 47 0.05 0.64
VLMT total, trial 1-5 44.43 15.66 34.15 11.75 4.48 1; 47 0.04 0.74
VLMT short delay 2.54 2.57 -0.65 1.46 14.28 1; 47 <0.01 1.53
VLMT long delay 2.80 2.82 2.29 2.96 0.21 1; 47 0.65 0.18
Cognitive flexibility
TMT-B (sec.) 106.78 50.52 139.29 82.79 1.63 1; 43 0.21* 0.47
Neutral/ emotive memory 0.01 2; 46 0.99
emotional memory 9.39 3.53 9.52 3.06 0.01 1; 47 0.92 0.04
neutral memory 6.72 3.37 6.87 3.04 0.02 1; 47 0.90 0.05
anCova = analysis of Covariance; ManCova = Multivariate analysis of Covariance; df = degrees of freedom; tMt =
trail Making test; vlMt = verbal learning Memory test; # with IQ, years since having a psychiatric diagnosis, young Mania
Rating scale scores, and current medication (antipsychotics; antidepressant & mood stabilizer) as covariates; *without years
since having a psychiatric diagnosis as covariate significant at P<0.05; **without yMRs scores or years since having a psychi-
atric diagnosis as covariates significant at P<0.05.
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tween the two groups; only two bipolar patients exhib-
ited  mild  alcohol  abuse.  young  Mania  Rating  scale
scores, years since having a psychiatric diagnosis, pre-
morbid IQ and current medication (i.e. frequency of
intake of antipsychotics or the combination of antide-
pressants and mood stabilizers) differed significantly
between the two groups. Hence, these variables were
included as covariates in the subsequent analyses. 
nEuRoCognItIvE funCtIon
as indicated in table 2, significant group differences
regarding  attention  and  psychomotor  speed  (Pillai’s
trace F = 6.94; df = 4;44; P <0.01) were found, even
when  controlled  for  possible  confounding  variables
(i.e. years since having a psychiatric diagnosis, premor-
bid IQ, yMRs scores and current medication). the dis  -
tinction  between  schizoaffective  and  bipolar  patients
accounted for 39% of the variance of the perfomance.
Consecutively applied anCova revealed that this re-
sult entirely arose from significant group differences
with the accurateness of the d2 test (F = 12.37; df =
1;47; P <0.01). schizoaffective patients also showed a
trend  towards  a  slower  psychomotor  speed  in  the
tMt-a test when there have been years since having a
psychiatric diagnosis (F = 6.42; df = 1;52; P = 0.01) or
the yMRs scores (F = 4.49; df = 1;49; P = 0.04) were
not used as covariates in the analysis (anCova).
similar findings resulted with regard to declarative
memory. ManCova indicated significant group dif-
ferences (Pillai’s trace F = 6.55; df = 5;43; P <0.01) ac-
counting for a total of 43% of the variance. this find-
ing  was  mainly  due  to  the  significant  lower  perfor-
mance of the patients with a schizoaffective disorder
in the vlMt short delay test (F = 14.28; df = 1;47;
P<0.01). furthermore, additional anCova without
the covariate of yMRs scores or without “years since
having  a  psychiatric  diagnosis”  revealed  a  trend  to-
wards a smaller digit span in the group of schizoaffec-
tive patients (F = 4.68, df = 1;52; P = 0.04).
this  notwithstanding,  no  significant  group  scores
were  found  with  regard  to  cognitive  flexibility  and
neutral  resp.  emotive  memory.  again,  an  anCova
with the covariate “years since having a psychiatric dia  -
gnosis” detected a trend towards less cognitive flexibil-
ity (tMt-B) in the group of schizoaffective patients
(F = 6.93, df = 1;47; P = 0.01). 
assoCIatIon of DEMogRaPHIC anD ClInICal
vaRIaBlEs on CognItIvE funCtIonIng
By means of a stepwise regression analyses variables
of potentially influencing cognitive functioning were
assessed separately for schizoaffective and bipolar pa-
tients. the effect of age, gender, years since having a
psychiatric  diagnosis,  hospitalisation  rate,  outpatient
treatment, premorbid IQ, young Mania Rating scale
scores and current medication were considered as vari-
ables. 
In the group of bipolar patients, all neuropsycho-
logical tests of attention and psychomotor speed were
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Table 3. Regression coefficients of the regression analyses in bipolar patients.
Dependend variable Predictor Standardized Beta tR 2
Attention and psychomotor speed
d2 speed (GZ) age -0.60 -3.74 0.36
d2 accurateness (F%) age 0.58 3.57 0.34
d2 concentration (KL) age -0,72 -5.13 0.51
TMT-A (sec.) age 0.64 4.15 0.41
Declarative memory
digit span forward age -0.52 -3.05 0.27
block span backward antidepressants & mood stabilizer -0.58 -4.63 0.68
age -3.30
-0.41
VLMT total, trial 1-5 age -0.74 -5.46 0.54
VLMT long delay Mood stabilizer only -0.50 -2.89 0.25
Cognitive flexibility
TMT-B (sec.) age 0.73 5.35 0.53
only results with p<0.01 are depicted.
Table 4. Regression coefficients of the regression analyses in schizoaffective patients.
Dependend variable Predictor Standardized Beta t R2
Attention and psychomotor speed
TMT-A (sec.) antidepressants & antipsychotics 0.88 6.69 0.78
Declarative memory
block span forward antidepressants & mood stabilizer -0.69 -3.43 0.48
Cognitive flexibility
TMT-B (sec.) age 0.74 3.63 0.55
only results with p<0.01 are depicted.
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variance explanation of d2 accurateness (cf. table 3).
Results of the declarative memory age as well as med-
ication were important variables for the tests. the use
of combined antidepressants and mood stabilizers to-
gether with the age accounted for 68% of the variance
concerning  the  block  span  backward.  the  intake  of
mood stabilizers predicted best the results of vlMt
long delay task, explaining 25% of the variance. the
patients’ age was one of the most relevant influencing
variables in the tMt-B test. 
In the group of schizoaffective patients, less mod-
els turned out to be significant. the tMt-a test was
best predicted by current use of antidepressants and
antipsychotics,  explaining  78%  of  the  variance  (cf.
table 4). Patients on antidepressants and mood stabi-
lizers performed worse in the block span forward task
and the medication accounted for 48% of the vari-
ance.  finally,  tMt-B,  a  test  representing  cognitive
flexibility, was most influenced by age.
DIsCussIon
the aim of this study was to evaluate neurocognitive
functioning of patients with schizoaffective disorder
(saD) and Bipolar I disorder (BD) patients in remis-
sion. there have already been a few studies that have
analysed the neuropsychological performance between
these two diagnostic entities. However, these studies
have not yet considered the extent of the differences
in neuropsychological test results and significant data
was used synonymously for the relevance of the test-
ing results. for this reason saD patients and BD pa-
tients were compared on various neurocognitive test
dimensions and the effect sizes were computed. addi-
tionally,  the  influence  of  demographic  and  clinical
variables on neuropsychological performance was also
analysed separately for each group. the samples dif-
fered with respect to psychopathology, premorbid in-
telligence, duration of illness and gender ratio with a
higher proportion of females in the saD group.
overall,  the  data  demonstrate  that  saD  patients
have  significantly  more  neuropsychological  dysfunc-
tion  and  worse  test  results  concerning  the  tasks  re-
garding attention as well as declarative memory. an ef-
fect size of 1.18 in d2-accurateness resp. 1.53 in the
vlMt short delay task, show large effects according
to Cohen’s classification [10]. In the ManCova the
item “years since having a psychiatric diagnosis” proved
to  be  an  important  covariate.  Putative  significant
group differences in the tMt-B test vanished after the
comparison was controlled for this variable. this is a
remarkable result, taking into account that executive
deficits in BD qualify as differential deficits, i.e. that
they significantly exceed deficits in other cognitive do-
mains [47]. thus, regardless of the remarkable dissimi-
larity the deficits are comparable with regard to the
severity. this is in accordance with previous studies in-
vestigating saD with most marked deficits in execu-
tive functioning [5]. 
our findings replicate the results found by torrent
et al. [48]. they also revealed significantly poorer per-
formance in attention and memory of saD patients
compared to BD patients. furthermore, in the present
study tMt-a and tMt-B test results were significant-
ly different in the anova, but not in the ManCo-
va. the putative differing results of szoke et al. [45]
turn out to be also in line with this lack of signifi-
cance. although the authors discuss similiar results of
subjects with sz and saD in the tMt test, there were
no  significant  differences  between  the  groups  at  all
apart from the comparison with the healthy control
group. additionally, they did not check demographic
charateristics,  though  the  saD  group  had  a  signifi-
cantly  lower  educational  level  than  the  BD  group.
Moreover,  the  fact  that  not  all  tests  of  declarative
memory revealed significant group differences is con-
sistent  with  the  findings  of  glahn  et  al.  [16].  they
found no significant difference in the digit span task
between saD and BD, albeit they only report the F
test for bipolar subjects with psychotic features. 
the  calculated  effect  sizes  indicate  a  remarkable
magnitude of cognitive differences between saD and
BD. the effect sizes for attention (d = 1.18) and de-
clarative memory (d = 1.53) exceed the effect sizes be-
tween sz and BD for the same neurocognitive domain
(d = 0.6 resp. d = 0.34) (seidman et al., 2002). Even
the  absolut  dysfunction  of  sustained  attention  and
verbal declarative memory in subjects with BD is less
stronger  (d  =  0.69  resp.  d  =  0.96  compared  with
healthy controls). similar effect sizes are reported by
schretlen et al. [42]. Even though there are no signifi-
cant differences in all of the cognitive domains, a con-
siderable  disparity  exists  in  specific  cognitive  func-
tions.  However,  these  studies  did  not  use  the  same
neuropsychological tests battery as in our study. seid-
man et al. [43], for instance, used a dichotomic listen-
ing task to assess attentional deficits, whereas the de-
clarative  memory  was  assessed  using  the  wechsler
Memory scale. 
a strength of our study was the careful controlling
for the effects of covariates. In the present study the
estimated premorbid IQ was lower in the saD than in
the BD sample. similar findings were reported from
Daban et al. (2006), who compared sz with BD pa-
tients.  notably,  the  worse  cognitive  functioning  of
saD patients persisted, even when controlling for the
premorbid IQ [4, 36]. It should be noted, that saD
patients had a longer history of diagnosed psychiatric
disorder of around 10 years compared to the BD pa-
tients, what may be due to a worse clinical course of
illness. In this study, we considered the age of onset of
the disorder as a covariate.
furthermore we did not distinguish between psy-
chotic or affective subtypes of schizoaffective disor-
der,  since  we  primarily  included  euthymic  patients.
Retrospectively, it was too vague to rely on the clinical
report to differentiate in both of these subgroups.
saD  patients  are  commonly  treated  with  psy-
chopharmacological  agents,  e.g.  antidepressants,  an-
tipsychotic medication or mood stabilizers to improve
psychotic  or  affective  symptoms  [29].  significant
group differences concerning medication were obvi-
ous  in  our  study  and,  consequently,  we  considered
medication as a confounding variable in our statistical
analysis.
our  results  regarding  the  association  of  demo-
graphic and clinical variables on cognitive functioning
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et al. [12] found that age and medication are relevant
variables influencing all cognitive domains in BD pa-
tients. the negative impact of medication on cognitive
performance  revealed  in  our  stepwise  regression
analyses is well in accordance with the study results of
Donaldson et al. [13] and savitz et al. [41]; for differ-
ing findings cf. Roiser et al. [39]. there is only sparse
data in the literature about cognitive functioning in a
separate group of saD patients. Results for saD pa-
tients are often merged with sz patients. Recently, Elie
et al. [14] reported that antipsychotic medication were
associated with poorer cognitive functioning in such a
combined group. our findings convincingly showed a
negative impact of medication on cognitive function-
ing. the variance was explained in up to 78% at maxi-
mum in the tMt-B test, what is remarkably a strong
effect. 
It is to consider that antipsychotic medication with
an  antidopaminergic  profile  (e.g.  D2/D3  receptor
anatgonism) has a strong negative influence on cogni-
tive functioning and depression. In our sample we as-
sumed these special mechanisms of antipsychotics not
to be a main factor to explain the differences of cog-
nitive functioning between both groups since saD pa-
tients  received  no  antipsychotic  monotherapy,  com-
bined therapy did not differ statistically significant be-
tween both samples and the ratio of substances with
an antidopaminergic profile was not different within
the groups. we concluded the effects to be similar in
both samples concering the antidopaminergic aspect
of medication.
Hence, apart from the mentioned class effects our
data did not allow further comments on the influence
on  cognition  of  distinct  psychotropic  compounds.
furthermore,  cognitive  impairment  resulted  particu-
larly under medication with combined agents, e.g. con-
current  intake  of  antidepressants,  antipsychotics  or
mood stabilizers.
finally, to refer to another aspect in the discusseion,
ferrier and thompson [15] criticised the weakness of
many  studies  not  to  control  for  residual  affective
symptoms. In our study we did not analyse the rele-
vance of affective symptoms, also, because of two dif-
ferent psychometric test scales applied in each sample
to  evaluate  depressive  symptomatology  (HaMD,
MaDRs). nevertheless, the fact that neither HaMD
in the BD group nor MaDRs in the saD group sig-
nificantly  correlated  with  the  cognitive  performance
questions the hypothesis of a strong influence of af-
fective symptoms on cognition in our study sample. 
our results may partly contribute to the discussion
of the nosological role of saD. Basically, there have
been three hypotheses discussed in the literature re-
garding the classification of saD in relation to sz and
affective disorder [29]. one of the hypotheses suggest
that saD is not a distinct entity at all. according to
this hypothesis, the whole category is recommended
to be abolished in favour of a broader concept of the
other disorders [28]. the second model assumes that
saD only represents the intersection of schizophrenia
and  affective  disorder  with  no  features  of  its  own.
Malhi et al. [29] describes saD to be “a point on a
continuum  of  affective-psychotic  psychopathology”.
finally, the third hypothesis ascribes saD to be a dis-
tinct entity in the spectrum of psychotic disorder. our
data rather contradicts the assumption of saD not to
exist as an entity. Cognitive impairment is obviously
more marked even when controlling the effects of co-
variates.  whether  it  is  a  severe  form  of  BD  in  the
spectrum of affective disorder or a separate entity still
remains in discussion.
the  main  methodological  shortcomings  of  our
study  are  the  small  sample  size  and  the  lack  of  a
healthy control group. the later is of importance as
the premorbid IQ was lower in the saD than in the
BD sample. It is to consider that the sample of saD
patients were not completly remitted concerning de-
pressive symptoms. Remission criteria for depression
were  evaluated  using  HaMD  in  the  BD  group  and
MaDRs in the saD sample. the use of MaDRs in
the saD group resulted of the better item structure
and test reliability of MaDRs compared to HaMD,
but was regretably not applied in the BD sample.
furthermore, we did not separate between patients
with  and  without  a  history  of  psychotic  symptoms.
since our sample consisted of euthymic resp. (partial-
ly) remitted patients, we did not obtain valid data con-
cerning  the  clinical  history  of  psychotic  symptoms
during the lifetime, retrospectively. these limitations
may contribute to blur the comparison of neuropsy-
chological test results of saD and BD patients. glahn
et al. [17] reported on worse results in the spatial de-
layed response task of BD patients with a lifetime his-
tory of psychotic features. 
additionally, future studies should consider the ef-
fect of medication in more detail. Due to the limited
sample size only a group-wise analysis of psychotropic
medication was calculated in our study, albeit marked
effects on cognition may result under treatment with
certain single compounds. a longitudinal study instead
of a cross-sectional design may further contribute to
more detailed results. 
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